Chinook Therapeutics, Inc. (NASDAQ: KDNY), relating to its proposed sale to Novartis AG. Under the terms of the agreement, KDNY shareholders are expected to receive $40.00 in cash per share they own and contingent value rights worth up to $4.00 per share.